Rigel Pharmaceuticals Inc (RIGL) stock
RIGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
$42.92−0.81 (-1.85%)
Close on Nov 17, 2026Market cap $801.74MP/E 2.7Yield –
Rigel Pharmaceuticals price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Rigel Pharmaceuticals's price to sales ratio was 3.2× on Nov 11, 2026, against 3.3× a year earlier. Over the last 5 years it ranged from 1.1× to 3.6×, with a median of 2.2×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 3.2× | +0.4 |
| 2025 | Dec 31, 2025 | 2.8× | +0.9 |
| 2024 | Dec 31, 2024 | 1.9× | −0.0 |
| 2023 | Dec 29, 2023 | 1.9× | −0.9 |
| 2022 | Dec 30, 2022 | 2.8× | −0.3 |
| 2021 | Dec 31, 2021 | 3.1× | −2.5 |
| 2020 | Dec 31, 2020 | 5.6× | +1.2 |
| 2019 | Dec 31, 2019 | 4.4× | −60.4 |
| 2018 | Dec 31, 2018 | 64.8× | +46.8 |
| 2017 | Dec 29, 2017 | 18.0× | – |
See a number that looks wrong?